- All Categories
- Aerospace
- Agricultural
- Analytical Instruments
- Avionics
- Biotechnology
- Chemicals
- Computer Hardware
- Computer Software
- Control Systems
- Data Processing/Analysis
- Defense
- Electrical and Electronics
- Energy
- Environmental
- Factory Automation
- Food Science and Nutrition
- Informatics
- Manufacturing Equipment
- Materials
- Mechanical
- Medical
- Nanotechnology
- Pharmaceutical
- Photonics
- Sensors and Actuators
- Subassemblies and Components
- Telecommunications and Internet
- Test and Measurement
- Transportation
- Veterinary
Currently Viewing: All Categories > Technology 00043
00043: A novel gene whose expression promotes differentiation of myeloid progenitor cells for use in cancer diagnostics and therapeutics.
Technology Categories
Biotechnology, Pharmaceutical, Test and Measurement, Veterinary
Keywords
Transcription, retinoic acid, myeloid cells, leukemia, transcription factor C/EBP protein
Background
CCAAT-enhancer-binding proteins (or C/EBPs) are a family of transcription factors that promote the expression of certain genes through interaction with their promoter. Once bound to DNA, C/EBPs can recruit so-called coactivators that, in turn, can open up chromatin structure, or recruit basal transcription factors. These proteins are found in hepatocytes, adipocytes, hematopoietic cells, spleen, kidney, brain and many others organs. C/EBPs proteins are involved in different cellular responses such as the control of cellular proliferation, growth and differentiation, metabolism, and immunology. Their expression is regulated at multiple levels through hormones, mitogens, cytokines, nutrients, and so on.
Leukemia is a diverse group of cancers that result in abnormal growth and differentiation of the blood
system. All trans retinoic acid (ATRA), marketed as Vesanoid, is an example of a cancer therapy that relies on differentiation of the cells to inhibit the abnormal growth of the cancer cells. It is used to treat at least one form of leukemia - adult promyelocytic leukemia (APML), and is is usually given together with other drugs. Vesanoid causes the immature blood cells to differentiate (i.e., mature) and die. Since the pathology of the leukemia is due to the highly proliferative immature cells, retinoic acid drives these cells to develop into functional cells which helps to alleviate the disease.
Leukemia is a diverse group of cancers that result in abnormal growth and differentiation of the blood
system. All trans retinoic acid (ATRA), marketed as Vesanoid, is an example of a cancer therapy that relies on differentiation of the cells to inhibit the abnormal growth of the cancer cells. It is used to treat at least one form of leukemia - adult promyelocytic leukemia (APML), and is is usually given together with other drugs. Vesanoid causes the immature blood cells to differentiate (i.e., mature) and die. Since the pathology of the leukemia is due to the highly proliferative immature cells, retinoic acid drives these cells to develop into functional cells which helps to alleviate the disease.
Description
Invention is a novel gene encoding transcription factor C/EBP Differential Display Product-1 (CDDP-1), that is involved in the differentiation of progenitor cells into neutrophils, monocytes/macrophages, mast cells, and/or red blood cells for use in cancer research, diagnostics, and therapeutics.
Benefits
- Better understanding of myeloid differentiation pathway: CDDP-1 regulation of myeloid cell differentiation will allow for the development of new and more effective leukemia diagnostics and therapeutics.
- Specific therapeutic targeting of undifferentiated myeloid cells: Over expression of CDDP-1 causes undifferentiated myeloid cells to develop into differentiated cells that can mature and die, ending the malignant cycle.
- May potentiate retinoic acid therapeutics: Treatment of cell lines with retonioic acid appears to induce the expression of CDDP-1.
- May delineate subtypes of leukemia/lymphomas: CDDP-1 is a novel cytoplasmic transcription factor whose expression levels may delineate subtypes of leukemia for more specific identification and treatment of leukemia.
Applications
This gene would be used by diagnostic and pharmaceutical companies to develop cancer diagnostic tests and therapeutic drugs. End users would include physicians and veterinarians.
IP Protection Status
US 6,605,710 (issued on 8/12/2003)
Additional Information
2005 Abstract on Gene Expression Profiling Identifies C/EBP as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation
http://ajrccm.atsjournals.org/cgi/content/short/176/6/602
Santa Cruz Biotechnology Inc. website provides C/EBP antibodies
http://www.scbt.com/table-c_ebp.html
2007 Article on Hope For Improved Leukemia Diagnosis And Treatment Using Molecular Detectors
http://www.medicalnewstoday.com/articles/77414.php
2009 article on Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
http://moffitt.org/CCJRoot/v16n2/pdf/132.pdf
http://ajrccm.atsjournals.org/cgi/content/short/176/6/602
Santa Cruz Biotechnology Inc. website provides C/EBP antibodies
http://www.scbt.com/table-c_ebp.html
2007 Article on Hope For Improved Leukemia Diagnosis And Treatment Using Molecular Detectors
http://www.medicalnewstoday.com/articles/77414.php
2009 article on Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
http://moffitt.org/CCJRoot/v16n2/pdf/132.pdf
Contact
For more information about this technology, please contact Mary Mayer at 517-355-2186 or mlmayer@msu.edu.